Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting

Excerpt from the Press Release:

– Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody –

– Kriya anticipates advancing KRIYA-586 into the clinic in 2025 to evaluate its safety and efficacy in people suffering from TED –

Click the button below to read the entire Press Release:

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, NC — Sept. 12, 2024 — Kriya Therapeutics, Inc., (Kriya), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced preclinical data from its gene therapy program for thyroid eye disease (TED). The data are being presented at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic & Reconstructive Surgery (ESOPRS) being held September 12-14 in Rotterdam, the Netherlands.

KRIYA-586 is an investigational adeno-associated virus (AAV) gene therapy product engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor (IGF1R), a key target implicated in the pathogenesis of TED. Currently, the only medicine approved in the U.S. for the treatment of TED is an intravenously infused human monoclonal antibody that blocks IGF1R. KRIYA-586 is designed for one-time delivery through a focal peribulbar injection performed in the office—with the goal of providing local and durable expression of anti-IGF1R antibody from transduced periorbital fat and muscle cells to help address the ocular manifestations of TED while minimizing systemic toxicities.

“We are excited to present these preclinical results that demonstrate the robust activity of KRIYA-586 in blocking IGF1R activity,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya. “These data support the potential of KRIYA-586 to address the unmet medical needs in thyroid eye disease, and we look forward to advancing KRIYA-586 into the clinic in 2025.”

Continue Reading The Press Release